Nicholas Vogelzang, M.D., oncologist and renowned investigator at Comprehensive Cancer Centers of Nevada (CCCN) of Las Vegas, is the most recent recipient of the prestigious Eugene P. Schonfeld Award from The Kidney Cancer Association (KCA). KCA, an organization that funds and promotes research projects to find a cure for kidney cancer, presented Vogelzang with the award when he gave the Eugene P. Schonfeld Memorial Lecture at the Ninth International Kidney Cancer Symposium on Oct. 1-2nd in Chicago.
“Dr. Vogelzang was instrumental in the founding of the KCA with Gene Schonfeld, and has contributed to the development of the new renal cell carcinoma treatment paradigm. In view of his significant contributions to the area, he is an outstanding recipient of the 2010 Schonfeld Award," asserted Ronald M. Bukowski, M.D., KCA Board of Directors member and chairperson of the KCA Medical and Scientific Steering Committee.
Dr. Vogelzang is specialized in genitourinary cancer and mesothelioma, a rare cancer of the lining of the lungs, heart, chest and abdomen that is generally caused by prolonged exposure to asbestos, and he is a highly respected medical oncologist and cancer investigator. Dr. Vogelzang is also the chair of the Developmental Therapeutics Committee and serves on the Research Executive Committee at US Oncology Research.
It is thanks to the expertise and tremendous work ethic of doctors and researchers like Dr. Vogelzang that discoveries on how to detect and treat cancer are being made daily, including advances in mesothelioma treatment. Their work generates hope that oncologists will soon have many more forms of cancer treatment to work with than surgery, chemotherapy and radiation. There is no cure for malignant mesothelioma.